ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

Defying critics, von Eschenbach describes hands-on role at NCI while running FDA. NCI is unified behind 2015 goal, he says.

December 9, 2005

ACS’ Freeman; Declare New War In Cancer; Poor Get Substandard Treatment, Lost Dignity

July 21, 1989

In Brief: AMA Opposes Bill To Permit Heroin Use For Pain Control, Says Morphine Is Equally As Effective

March 23, 1984

Dingell To Challenge NCI, NSABP Handling Of Fraud, Delays

April 8, 1994

Groups Urge FDA To Take Action Against Tobacco Products

June 27, 2014

In Brief: Money Bill Delay Seen Until After Election ACCC Meeting Planned On Community Programs

September 15, 1978